Can these three biomedical technology companies become the “toon†of investors?
Investors and analysts are keen to guess which company will be acquired by another company. Although this year's M&A activity has cooled down compared with the previous two years, there are still a lot of transactions taking place. The following three biotech stocks may become the next bidder.
BioMarin Pharmaceutical
BioMarin Pharmaceutical may not be discussed for the first time. In June, there were rumors that if Sanofi’s bid for the US cancer drug company Medivition failed, the French pharmaceutical giant would turn its attention to BioMarin.
BioMarin is headquartered in California, USA, and its famous reputation is the failed Duchenne muscular dystrophy drug Kyndrisa (drisaspersen). In January of this year, after the drug application was rejected by the US Food and Drug Administration, BioMarin terminated the project and three other first-generation follow-up products, BMN 044, BMN 045 and BMN 053, all of which were in treatment. The second phase of the trial of Duchenne muscular atrophy.
Companies interested in BioMarin may be interested in the company's non-Dut's muscular dystrophy drug pipelines, such as rare genetic diseases. At present, the company has five products on the market: Vimizim for treating Morquio A syndrome, Kuvan for treating phenylketonuria, Naglazyme for treating type VI mucopolysaccharide, Aldurazyme for treating type I mucopolysaccharidosis, and treating muscle weakness. Syndapse of the syndrome. The company also has a product line for the treatment of achondroplasia, the treatment of late-infant neuronal waxy lipofuscinosis, hemophilia A and Shafilipo syndrome.
Analysts say Roche may be a buyer. BioMarin is currently trading at $94.51.
Incyte Corporation
Incyte Corporation is headquartered in Delaware, USA, and there have been recent rumors that it may be acquired by Amgen. Incyte specializes in the oncology field, and Amgen's oncology business is strong, but is facing multiple patent expirations and the challenge of biosimilar competition.
The only approved drug for Incyte is Jakafi, which accounts for 70% of the company's revenue. The drug is expected to become a heavyweight with sales of $1 billion by 2020. Incyte's product pipeline also includes nine other cancer drugs, three of which are kinase inhibitors. In addition to Amgen, another potential buyer mentioned is Hill Pharmaceuticals.
Incyte's current share price is $80.80.
Frozen Octopus,Octopus Frozen Seafood,Frozen Seafood Octopus,Octopus In Flower Shape
Zhejiang Zhoushan Jiaze Aquatic Co., Ltd. , https://www.tianjia-aquatics.com